What is the official website of Intas Pharmaceuticals ?

The official website of Intas Pharmaceuticals is https://intaspharma.com.

What is Intas Pharmaceuticals's cybersecurity risk score?

Intas Pharmaceuticals has an AI-generated cybersecurity risk score of 795 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Intas Pharmaceuticals experienced?

According to Rankiteo, Intas Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Intas Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Intas Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Intas Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Intas Pharmaceuticals is not certified under SOC 2 Type 1.

Does Intas Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Intas Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Intas Pharmaceuticals comply with GDPR ?

According to Rankiteo, Intas Pharmaceuticals is not listed as GDPR compliant.

Does Intas Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Intas Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Intas Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Intas Pharmaceuticals is not compliant with HIPAA regulations.

Does Intas Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Intas Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Intas Pharmaceuticals operate in ?

Intas Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Intas Pharmaceuticals have ?

Intas Pharmaceuticals employs approximately 18,773 people worldwide.

Does Intas Pharmaceuticals own any subsidiaries ?

Intas Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Intas Pharmaceuticals have ?

Intas Pharmaceuticals's official LinkedIn profile has approximately 855,228 followers.

What is the NAICS classification code for Intas Pharmaceuticals ?

Intas Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Intas Pharmaceuticals have a Crunchbase profile ?

No, Intas Pharmaceuticals does not have a profile on Crunchbase.

Does Intas Pharmaceuticals have a LinkedIn profile ?

Yes, Intas Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/intas-pharmaceuticals.

How many cybersecurity incidents has Intas Pharmaceuticals experienced ?

As of June 25, 2026, Rankiteo reports that Intas Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Intas Pharmaceuticals have ?

Intas Pharmaceuticals has an estimated 5,696 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Intas Pharmaceuticals

Boost Score +25 with badge (5 left)

795

/1000

Fair

820

/1000

Good

Intas Pharmaceuticals Vendor Cyber Rating & Cyber Score

intaspharma.com

Add Your Compliance Badge

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India.

Intas Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Intas Pharmaceuticals

Intas Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Intas Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Intas Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incident Types Intas Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Intas Pharmaceuticals in 2026.

Incident History - Intas Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Intas Pharmaceuticals Subsidiaries

Intas Pharmaceuticals

Pharmaceutical Manufacturing

Website: https://intaspharma.com

Company Size: 10,000+ employees

Intas B2BPharmaceutical Manufacturing

Loading…

Intas Pharmaceuticals Similar Companies

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

Intas Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 18, 2025 08:00 AM

Intas Pharmaceuticals Appoints Dr. Pramod Kharwade as VP- Formulation & Development

Intas Pharmaceuticals has announced the appointment of Dr. Pramod Kharwade as the Vice President of Formulation and Development.

Read Article

December 20, 2022 08:00 AM

Sumeet Khokhani joins Reliance Industries as VP Cybersecurity

Cybersecurity expert Sumeet Khokhani has joined Reliance Industries as Vice President - IRM & Cybersecurity. Before joining Reliance...

Read Article

September 06, 2010 07:00 AM

Intas Pharma plans Rs.800 Crore IPO to fund acquisitions

Intas Pharmaceuticals, an Ahmedabad-based company, is planning for a public issue of 750-800 crore with an objective to raise fresh funds for acquisitions.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56785

SUMMARY

FlatPress versions prior to commit 10be83c, contains a stored cross-site scripting vulnerability in comment and contact forms where name, URL, and email fields are rendered without proper output encoding in Smarty templates. Attackers can inject arbitrary HTML and JavaScript through these fields to execute malicious scripts in browsers of viewers including administrators, or bypass URL scheme validation to inject javascript: or data: URIs.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 8.2)

cvss3

Base Score: 8.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-54588

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 use the attacker-controlled `HTTP_HOST` request header as the authoritative source for building callback URLs in its OIDC, SAML, and logout authentication flows without any validation. An unauthenticated attacker can poison the `redirect_uri` sent to the Identity Provider, causing the IdP to redirect the victim's authorization code to an attacker-controlled server - resulting in full account takeover with no credentials required. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-48493

SUMMARY

Snipe-IT is an IT asset/license management system. In versions prior to 8.6.0, a user with only users.edit can send a PATCH to /api/v1/users/{their_own_id} and grant themselves any permission except admin and superuser — for example `assets.view`, `assets.create`, `reports.view`, import, etc. The issue is patched in version 8.6.0.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:H/A:N

Impact Score

4.2

Exploitability

1.2

REFERENCES

CVE-2026-47693

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 are vulnerable to CSV Injection (Formula Injection) in its log export functionality. User-controlled data — specifically the username field — is written to exported CSV files without sanitizing formula trigger characters (=, +, -, @). When an administrator exports activity logs and opens the resulting CSV in a spreadsheet application (Microsoft Excel, LibreOffice Calc, Google Sheets), any formula stored in a username is executed by the application. This can be used for phishing attacks against administrators or data exfiltration. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 6.9)

cvss3

Base Score: 6.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:H/I:L/A:N

Impact Score

4.7

Exploitability

1.7

REFERENCES

CVE-2026-12164

SUMMARY

Fortra File Integrity Monitoring (FIM), formerly Tripwire Enterprise, versions prior to 9.4.0 may assign incorrect or elevated effective permissions to users created by the tetool import command while FIM is running, particularly when the import also creates or changes roles or role-permission relationships.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 4.4)

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

0.8

REFERENCES

https://www.fortra.com/security/advisories/product-security/fi-2026-010

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…